CADTH to Become the Canada's Drug Agency

As announced on December 18 by the Government of Canada, CADTH will become the Canada's Drug Agency (CDA-AMC).

We are excited and humbled by this opportunity. It builds on the trust we have established within the pan-Canadian drugs and devices environment, and our strong history of providing health leaders across Canada with credible, objective evidence to make informed decisions about our health care systems.

As we build the CDA-AMC, we will expand our expertise and role in the pharmaceuticals sector, while upholding the core principles that guide the organization. We will also continue our important work in other areas like health technology assessment and post-market safety and effectiveness.

We are moving forward to bring the CDA-AMC to life, in partnership with provinces and territories and the federal government, and informed by work at the Canada's Drug Agency Transition Office (CDATO). Collaborating with governments, patients, clinicians, Indigenous leaders, and industry will be critical to build an effective CDA-AMC.

Establishing the CDA-AMC will allow us to make a more substantial contribution to Canada’s health systems to help people access and afford the prescription drugs they need for better health.

CADTH would like to acknowledge and thank Susan Fitzpatrick for her leadership of the CDATO, and her team’s work to develop a vision, mandate, and plan to establish the CDA-AMC.